- Home
- API vs TCRX Comparison
API vs TCRX Comparison
Compare API & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- API
- TCRX
- Stock Information
- Founded
- API 2013
- TCRX 2018
- Country
- API United States
- TCRX United States
- Employees
- API N/A
- TCRX N/A
- Industry
- API Computer Software: Prepackaged Software
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- API Technology
- TCRX Health Care
- Exchange
- API Nasdaq
- TCRX Nasdaq
- Market Cap
- API 223.6M
- TCRX 257.5M
- IPO Year
- API 2020
- TCRX 2021
- Fundamental
- Price
- API $4.39
- TCRX $4.41
- Analyst Decision
- API
- TCRX Strong Buy
- Analyst Count
- API 0
- TCRX 5
- Target Price
- API N/A
- TCRX $11.40
- AVG Volume (30 Days)
- API 1.5M
- TCRX 261.6K
- Earning Date
- API 11-25-2024
- TCRX 11-12-2024
- Dividend Yield
- API N/A
- TCRX N/A
- EPS Growth
- API N/A
- TCRX N/A
- EPS
- API N/A
- TCRX N/A
- Revenue
- API $138,287,000.00
- TCRX $9,362,000.00
- Revenue This Year
- API N/A
- TCRX N/A
- Revenue Next Year
- API $8.09
- TCRX $3.10
- P/E Ratio
- API N/A
- TCRX N/A
- Revenue Growth
- API N/A
- TCRX N/A
- 52 Week Low
- API $1.65
- TCRX $3.73
- 52 Week High
- API $6.43
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- API 61.20
- TCRX 34.37
- Support Level
- API $4.00
- TCRX $5.03
- Resistance Level
- API $5.47
- TCRX $6.23
- Average True Range (ATR)
- API 0.53
- TCRX 0.43
- MACD
- API 0.11
- TCRX -0.05
- Stochastic Oscillator
- API 60.73
- TCRX 5.22
About API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.